Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273978 | 0.87 | MAPT (0.41) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL21273982 | 0.87 | MAPT (0.41) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL21285512 | 0.83 | KMT2A (0.43) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL21285522 | 0.82 | MAPT (0.39) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL22822491 | 0.82 | MAPT (0.39) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL21274294 | 0.81 | MAPT (0.38) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL21285529 | 0.81 | MAPT (0.38) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL21274292 | 0.81 | MAPT (0.38) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL21273994 | 0.80 | MAPT (0.37) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL21274081 | 0.80 | MAPT (0.37) | KMT2AMEN1TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | EVOTEC (UK) LTD (GB) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399268-A1 | Pharmaceutical 6,5 Heterobicyclic Ring Derivatives | STING1, IRF3, NFATC1 | KMT2A 4561/4885MEN1 3236/4885TP53 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.